Patents by Inventor Robert J. Pelham

Robert J. Pelham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190256923
    Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 22, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Dominick SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
  • Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Publication number: 20160222463
    Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Dominick S. SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
  • Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Publication number: 20140303002
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 9, 2014
    Applicant: Genomic Health, Inc.
    Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Publication number: 20140296085
    Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 2, 2014
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. Baker, Dominick S. Sinicropi, Robert J. Pelham, Michael R. Crager, Francois Collin, James C. Stephans, Mei-Lan Liu, John D. Morlan, Kunbin Qu
  • Patent number: 8725426
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: May 13, 2014
    Assignee: Genomic Health, Inc.
    Inventors: Steve Shak, Mark Lee, William Novotny, Tara Maddala, Michael Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Publication number: 20130274127
    Abstract: The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 17, 2013
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. Baker, Robert J. Pelham, Kevin A. Kwei
  • Publication number: 20120046186
    Abstract: The present invention provides methods for predicting a likelihood that a patient with cancer will exhibit a positive response to a treatment with a platinum-based chemotherapy drug. The methods generally involve determining an expression level of a gene product that correlates with responsiveness to treatment with a platinum-based chemotherapy drug. In an embodiment of the invention, the platinum-based chemotherapy drug is oxaliplatin, and the cancer is colorectal cancer.
    Type: Application
    Filed: August 16, 2011
    Publication date: February 23, 2012
    Inventors: ROBERT J. PELHAM, KELLY A. HARRADINE, JOFFRE B. BAKER
  • Publication number: 20120028264
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 2, 2012
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker